Results 51 to 60 of about 67,058 (255)

GM‐CSF Promotes Neutrophil PD‐L1 Expression Through the VEGFR‐2/STAT6/CSF2 Signaling Axis in Oral Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
VEGFR‐2 signaling in OSCC activates Src–STAT6‐dependent CSF2 transcription, driving tumor‐derived GM‐CSF secretion. GM‐CSF programs neutrophils to express PD‐L1 through STAT5–mTOR/S6K signaling, suppressing cytotoxic CD8+ T cells. This pathway reveals a tumor–neutrophil immune checkpoint circuit that limits anti‐PD‐1 responsiveness in OSCC.
Fangxing Zhu   +13 more
wiley   +1 more source

Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT‐SAAWP RACE Study

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano   +52 more
wiley   +1 more source

Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome

open access: yesHaematologica, 2008
Expression of a NUP98-HOXD13 (NHD13) fusion gene, initially identified in a patient with myelodysplastic syndrome, leads to a highly penetrant myelodysplastic syndrome in mice that recapitulates all of the key features of the human disease.
Chul Won Choi   +3 more
doaj   +1 more source

The Homozygous p.(Arg215Ter) Variant in XRCC2 Is Associated With Atypical Fanconi Anemia Without Major Hematological Abnormalities in Childhood

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Fanconi Anemia (FA) is the most frequent inherited bone marrow failure syndrome. A role for the XRCC2 gene in FA was suspected in 2012 and confirmed in 2016, but only two affected individuals have been described thus far, and no long‐term follow‐up is available.
Sabina Cenciarelli   +11 more
wiley   +1 more source

Concurrent Germline RB1 & Mosaic TP53 in a Child With Multiple Childhood Cancers

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT We report a patient with a pathogenic germline variant (PGV) in RB1 and somatic mosaicism for a pathogenic TP53 variant who developed three distinct types of childhood cancer: retinoblastoma, osteosarcoma, and myelodysplastic syndrome (MDS) before the age of 6 years.
Ole Haubjerg Nielsen   +8 more
wiley   +1 more source

TELOMERE LENGHT AND CYTOPENIAS: ANALYSIS OF CHILDREN REFERRED TO BRAZILIAN COOPERATIVE GROUP OF CHILDHOOD MYELODYSPLASTIC SYNDROME

open access: yesEJC Paediatric Oncology, 2023
Rafael Balceiro   +5 more
doaj   +1 more source

Acute myeloid leukemia in a father and son with a germline mutation of ASXL1

open access: yesBiomarker Research, 2018
Background Myelodysplastic syndromes and acute myeloid leukemia usually occur sporadically in older adults. More recently cases of familial acute myeloid leukemia and/or myelodysplastic syndrome have been reported. Case presentation Currently we report a
Karen Seiter   +3 more
doaj   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm   +2 more
wiley   +1 more source

JUVENILE MYELOMONOCYTIC LEUKEMIA WITH TELOMERE SHORTENING: CASE REPORT

open access: yesEJC Paediatric Oncology, 2023
Anita Frisanco Oliveira   +3 more
doaj   +1 more source

Myelodysplastic syndromes and overlap syndromes

open access: yesBLOOD RESEARCH, 2021
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological neoplasms characterized by ineffective hematopoiesis, morphologic dysplasia, and cytopenia. MDS overlap syndromes include various disorders, such as myelodysplastic/myeloproliferative neoplasms and hypoplastic MDS with aplastic anemia characteristics.
openaire   +3 more sources

Home - About - Disclaimer - Privacy